Gossamer Bio, Inc. (GOSS) Form 8-K — Aug 21, 2026
Gossamer Bio has entered a securities purchase agreement for a two-stage private placement expected to bring in approximately $25.0 million at an initial closing on August 24, 2026, plus approximately $125.0 million at a second closing triggered if the FDA accepts the filing of its seralutinib NDA for pulmonary arterial hypertension in 2026. Investors will also receive FDA Approval Warrants that become exercisable only if seralutinib receives FDA approval, which could deliver roughly $100.0 million more at $0.187 per share. Leerink Partners and Cantor Fitzgerald acted as placement agents.
Key figures
- Gross Proceeds
- Approximately $25.0 million at Initial Closing plus approximately $125.0 million at Second Closing ($150.0 million total committed)
- Expected runway
- funds operating plan into 2028
- Initial closing date
- August 24, 2026
- Preferred stated value
- $1,000.00 per share
- Total potential proceeds
- $250.0 million
- Fda warrant exercise price
- $0.187
- Series a1 preferred shares
- 25,000
- Series a2 preferred shares
- 125,000
- Series a3 preferred shares
- 100,000
- Fda warrant exercise proceeds
- $100.0 million if exercised in full
- Second closing gross proceeds
- $125.0 million, contingent on FDA accepting seralutinib NDA filing in 2026
- Initial closing gross proceeds
- $25.0 million
- Initial closing price per share
- $0.14
- Shares issuable initial closing
- 178,699,081 common shares
- Pre approval liquidation preference
- 4x stated value
- Shares issuable fda approval warrants
- 534,759,377 common shares
- Initial closing prefunded warrant price
- $0.1399
Price after filing
Close on the filing date to close N calendar days later (from $12.38). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.